ABL Bio is showing a correction trend, falling more than 7,000 won intraday on the 18th. As volatility across the overall bio sector has increased recently, profit-taking sell-offs accumulated during the stock's upward run and rotational buying across individual stocks have pushed selling pressure to the forefront.

On this day, ABL Bio is drawing market attention as it trades at a price more than 7,000 won lower than the previous trading day. With rotational buying taking place within the sector, the stock is undergoing a short-term correction.

ABL Bio is a company developing anti-cancer drugs and treatments for degenerative brain diseases based on its bispecific antibody platform technology. In particular, it is regarded as a representative bio stock that has attracted expectations for technology export deals with global pharmaceutical companies, leveraging its blood-brain barrier (BBB) shuttle platform called 'Grabbody-B.'

The market cites 'expansion of technology export contracts' and 'clinical progress of key pipelines' as the core variables that will determine ABL Bio's corporate value going forward. It is expected that the outcomes of collaborations with global pharmaceutical companies will have a decisive impact on future stock price momentum.

Investors are keeping a close watch on forthcoming clinical trial results, news related to technology transfers, and research and development (R&D) achievements. It is also worth noting that, given the nature of the bio sector, stock price volatility could expand further depending on such key news.

[※ This article was written with the assistance of AI. Investment decisions are the responsibility of the individual investor, and the content contained in this article may change depending on market conditions.]